acifran has been researched along with Dyslipidemia in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Boatman, PD; Richman, JG; Semple, G | 1 |
Chen, R; Connolly, DT; Dang, TH; Pride, CC; Richman, JG; Sage, CR; Semple, G; Skinner, PJ; Tamura, SY; Webb, PJ | 1 |
1 review(s) available for acifran and Dyslipidemia
Article | Year |
---|---|
Nicotinic acid receptor agonists.
Topics: Animals; Chemistry, Pharmaceutical; Drug Design; Dyslipidemias; Humans; Kinetics; Ligands; Mice; Models, Chemical; Nicotinic Agonists; ortho-Aminobenzoates; Receptors, G-Protein-Coupled; Receptors, Nicotinic | 2008 |
1 other study(ies) available for acifran and Dyslipidemia
Article | Year |
---|---|
5-N,N-Disubstituted 5-aminopyrazole-3-carboxylic acids are highly potent agonists of GPR109b.
Topics: Animals; Atherosclerosis; Carboxylic Acids; Chemistry, Pharmaceutical; CHO Cells; Cricetinae; Cricetulus; Drug Design; Dyslipidemias; Humans; Ligands; Lipoproteins, HDL; Lipoproteins, LDL; Models, Chemical; Niacin; Pyrazoles; Receptors, G-Protein-Coupled; Receptors, Nicotinic | 2009 |